Creation of other subsets was based on potential clinical therapeutic utility, with 2-gene subset and 3-gene subset reflecting the gene biomarkers utilized for approval of PARP inhibitors in the management of breast, ovarian, pancreatic and prostate cancers. The gene discussed is PARP1; the disease is prostate cancer.